Počet záznamů: 1  

Enhanced Topical and Transdermal Delivery of Antineoplastic and Antiviral Acyclic Nucleoside Phosphonate cPr-PMEDAP

  1. 1.
    SYSNO ASEP0370825
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevEnhanced Topical and Transdermal Delivery of Antineoplastic and Antiviral Acyclic Nucleoside Phosphonate cPr-PMEDAP
    Tvůrce(i) Vávrová, K. (CZ)
    Kovaříková, P. (CZ)
    Školová, B. (CZ)
    Líbalová, M. (CZ)
    Roh, J. (CZ)
    Čáp, R. (CZ)
    Holý, Antonín (UOCHB-X)
    Hrabálek, A. (CZ)
    Celkový počet autorů8
    Zdroj.dok.Pharmaceutical Research. - : Springer - ISSN 0724-8741
    Roč. 28, č. 12 (2011), s. 3105-3115
    Poč.str.11 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaacyclic nucleoside phosphonates ; antivirals ; antineoplastics ; permeation enhancer ; topical skin application ; transdermal delivery
    Vědní obor RIVCC - Organická chemie
    CEP1M0508 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy
    CEZAV0Z40550506 - UOCHB-X (2005-2011)
    UT WOS000297710200014
    DOI10.1007/s11095-011-0508-4
    AnotaceAcyclic nucleoside phosphonates possess unique antiviral and antineoplastic activities; however, their polar phosphonate moiety is associated with low ability to cross biological membranes. We explored the potential of transdermal and topical delivery of 2,6-diaminopurine derivative cPr-PMEDAP. In vitro diffusion of cPr-PMEDAP was investigated using formulations at different pH and concentration and with permeation enhancer through porcine and human skin. Ability of 0.1-5% cPr-PMEDAP to cross human skin barrier was very low with flux values similar to 40 ng/cm(2)/h, the majority of compound found in the stratum corneum. The highest permeation rates were found at pH 6; increased donor concentration had no influence. The permeation enhancer dodecyl 6-dimethylaminohexanoate (DDAK, 1%) increased flux of cPr-PMEDAP (up to 61 times) and its concentration in nucleated epidermis (up to similar to 0.5 mg of cPr-PMEDAP/g of the tissue). No deamination of cPr-PMEDAP into PMEG occurred during permeation studies, but N-dealkylation into PMEDAP mediated by skin microflora was observed. Transdermal or topical application of cPr-PMEDAP enabled by the permeation enhancer DDAK may provide an attractive alternative route of administration of this potent antitumor and antiviral compound.
    PracovištěÚstav organické chemie a biochemie
    Kontaktasep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434
    Rok sběru2012
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.